Spruce Biosciences Secures Up to $50M Debt Facility with Warrants to Extend Runway

summarizeSummary

Spruce Biosciences secured a loan and security agreement for up to $50 million, with an initial $15 million tranche, to fund operations into 2027 and advance its TA-ERT program for MPS IIIB.

check_boxKey Events

• Secured $50M Debt Facility

  Spruce Biosciences entered a Loan and Security Agreement for up to $50 million in growth capital with Avenue Capital Management II, L.P.

• Initial $15M Funding

  An initial tranche of $15 million will be funded within five business days, which is expected to extend the company's cash runway into 2027.

• Milestone-Based Tranches

  An additional $35 million is available in three tranches, contingent on achieving key regulatory and commercial milestones for its TA-ERT program for MPS IIIB.

• Expensive Financing Terms

  The facility includes a high interest rate (minimum 12.25%), an all-asset lien, warrants for $3.2 million worth of common stock, and a conversion option for up to $4 million of principal at a premium to the warrant exercise price, indicating significant potential dilution.

auto_awesomeAnalysis

Spruce Biosciences entered into a material definitive agreement for a debt facility totaling up to $50 million, with an initial $15 million funded immediately. This financing is crucial for extending Spruce Biosciences' cash runway into 2027 and supporting the development and potential launch of its tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfillipo Syndrome Type B (MPS IIIB). While the funding provides essential liquidity and operational continuity for a late-stage biopharmaceutical company, the terms are notably expensive, including a high interest rate (minimum 12.25%), an all-asset lien, and significant potential dilution through warrants and a conversion option for up to $4 million of principal. The additional tranches are contingent on achieving key regulatory and commercial milestones, adding a performance-based element to future funding. Investors should monitor the company's progress on these milestones and the impact of the financing terms on shareholder value.